Suppr超能文献

B 细胞白血病 3(Bcl-3)蛋白通过与核因子 κB(NF-κB)p50 相互作用抑制转录。

Inhibition of transcription by B cell Leukemia 3 (Bcl-3) protein requires interaction with nuclear factor κB (NF-κB) p50.

机构信息

Department of Biochemistry, University College Cork, Cork, Ireland.

Department of Life Sciences and the Materials and Surface Science Institute, University of Limerick, Limerick, Ireland.

出版信息

J Biol Chem. 2014 Mar 7;289(10):7059-7067. doi: 10.1074/jbc.M114.551986. Epub 2014 Jan 23.

Abstract

B cell leukemia 3 (Bcl-3) is an essential negative regulator of NF-κB during Toll-like receptor and TNF receptor signaling. Bcl-3 also interacts with a number of transcriptional regulators, including homodimers of the NF-κB p50 subunit. Deletion of Bcl-3 results in increased NF-κB p50 ubiquitination and proteasomal degradation and increased inflammatory gene expression. We employed immobilized peptide array technology to define a region of p50 required for the formation of a Bcl-3·p50 homodimer immunosuppressor complex. Our data demonstrate that amino acids 359-361 and 363 of p50 are critical for interaction with Bcl-3 and essential for Bcl-3-mediated inhibition of inflammatory gene expression. Bcl-3 is unable to interact with p50 when these amino acids are mutated, rendering it incapable of inhibiting the transcriptional activity of NF-κB. Bcl-3 interaction-defective p50 is hyperubiquitinated and has a significantly reduced half-life relative to wild-type p50. Nfkb1(-/-) cells reconstituted with mutated p50 precursor p105 are hyperresponsive to TNFα stimulation relative to wild-type p105, as measured by inflammatory gene expression. Mutant p105 recapitulates a Bcl3(-/-) phenotype. This study demonstrates that interaction with p50 is necessary and sufficient for the anti-inflammatory properties of Bcl-3 and further highlights the importance of p50 homodimer stability in the control of NF-κB target gene expression.

摘要

B 细胞白血病 3(Bcl-3)是 Toll 样受体和 TNF 受体信号转导过程中 NF-κB 的必需负调控因子。Bcl-3 还与许多转录调节因子相互作用,包括 NF-κB p50 亚基的同源二聚体。Bcl-3 的缺失导致 NF-κB p50 的泛素化和蛋白酶体降解增加,以及炎症基因表达增加。我们采用固定化肽阵列技术来定义 p50 的一个区域,该区域对于形成 Bcl-3·p50 同源二聚体免疫抑制复合物是必需的。我们的数据表明,p50 的氨基酸 359-361 和 363 对于与 Bcl-3 的相互作用是关键的,对于 Bcl-3 介导的炎症基因表达抑制是必需的。当这些氨基酸发生突变时,Bcl-3 无法与 p50 相互作用,从而使其无法抑制 NF-κB 的转录活性。与野生型 p50 相比,Bcl-3 相互作用缺陷的 p50 高度泛素化,半衰期显著缩短。与野生型 p105 相比,用突变的 p50 前体 p105 重建的 Nfkb1(-/-)细胞对 TNFα 刺激的反应更为敏感,这可以通过炎症基因表达来衡量。突变的 p105 重现了 Bcl3(-/-)表型。本研究表明,与 p50 的相互作用对于 Bcl-3 的抗炎特性是必需和充分的,并且进一步强调了 p50 同源二聚体稳定性在控制 NF-κB 靶基因表达中的重要性。

相似文献

1
Inhibition of transcription by B cell Leukemia 3 (Bcl-3) protein requires interaction with nuclear factor κB (NF-κB) p50.
J Biol Chem. 2014 Mar 7;289(10):7059-7067. doi: 10.1074/jbc.M114.551986. Epub 2014 Jan 23.
4
Identification of genes that elicit disuse muscle atrophy via the transcription factors p50 and Bcl-3.
PLoS One. 2011 Jan 13;6(1):e16171. doi: 10.1371/journal.pone.0016171.
5
6
BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages.
J Biol Chem. 2004 Nov 26;279(48):49995-50003. doi: 10.1074/jbc.M404246200. Epub 2004 Oct 1.
9
The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
Oncogene. 1999 Jun 3;18(22):3316-23. doi: 10.1038/sj.onc.1202717.
10
Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade.
Science. 2007 Aug 3;317(5838):675-8. doi: 10.1126/science.1142953.

引用本文的文献

1
The NF-κB signaling network in the life of T cells.
Front Immunol. 2025 Apr 30;16:1559494. doi: 10.3389/fimmu.2025.1559494. eCollection 2025.
2
Regulation and Function of the Atypical IκBs-Bcl-3, IκB, and IκBζ-in Lymphocytes and Autoimmunity.
Eur J Immunol. 2025 May;55(5):e202451273. doi: 10.1002/eji.202451273.
3
Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).
Mol Med Rep. 2024 Dec;30(6). doi: 10.3892/mmr.2024.13344. Epub 2024 Oct 4.
4
5
Identification and Interpretation of eQTL and eGenes for Hodgkin Lymphoma Susceptibility.
Genes (Basel). 2023 May 24;14(6):1142. doi: 10.3390/genes14061142.
6
MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Cell Oncol (Dordr). 2023 Oct;46(5):1213-1234. doi: 10.1007/s13402-023-00805-w. Epub 2023 May 11.
7
Bcl-3: A Double-Edged Sword in Immune Cells and Inflammation.
Front Immunol. 2022 Mar 10;13:847699. doi: 10.3389/fimmu.2022.847699. eCollection 2022.
8
Transcription Coactivator BCL3 Acts as a Potential Regulator of Lipid Metabolism Through the Effects on Inflammation.
J Inflamm Res. 2021 Sep 23;14:4915-4926. doi: 10.2147/JIR.S327858. eCollection 2021.
9
Inhibitory feedback control of NF-κB signalling in health and disease.
Biochem J. 2021 Jul 16;478(13):2619-2664. doi: 10.1042/BCJ20210139.
10
Target acquired: transcriptional regulators as drug targets for protozoan parasites.
Int J Parasitol. 2021 Jul;51(8):599-611. doi: 10.1016/j.ijpara.2020.12.007. Epub 2021 Mar 13.

本文引用的文献

1
Deubiquitination of NF-κB by Ubiquitin-Specific Protease-7 promotes transcription.
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):618-23. doi: 10.1073/pnas.1208446110. Epub 2012 Dec 24.
2
Nuclear factor-κB binding motifs specify Toll-like receptor-induced gene repression through an inducible repressosome.
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14140-5. doi: 10.1073/pnas.1119842109. Epub 2012 Aug 13.
5
BAG-1 interacts with the p50-p50 homodimeric NF-κB complex: implications for colorectal carcinogenesis.
Oncogene. 2012 May 31;31(22):2761-72. doi: 10.1038/onc.2011.452. Epub 2011 Oct 3.
7
Insulin receptor substrate-3, interacting with Bcl-3, enhances p50 NF-kappaB activity.
Biochem Biophys Res Commun. 2010 Apr 9;394(3):697-702. doi: 10.1016/j.bbrc.2010.03.054. Epub 2010 Mar 11.
10
Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription.
Immunol Res. 2008;42(1-3):210-8. doi: 10.1007/s12026-008-8075-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验